Showing 51–60 of 80 results from Publika

Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC (2007)
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure
Hypertension, 49 (5), 1128-33
PubMed 17325237 DOI 10.1161/HYPERTENSIONAHA.106.083832
Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC (2006)
BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors
J Cell Physiol, 209 (3), 943-9
PubMed 16986166 DOI 10.1002/jcp.20793
Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC (2006)
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure
J Am Soc Nephrol, 17 (10), 2742-7
PubMed 16928803 DOI 10.1681/ASN.2006020161
Belluardo P, Cataliotti A, Bonaiuto L, Giuffrè E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS (2006)
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
Am J Physiol Heart Circ Physiol, 291 (4), H1529-35
PubMed 16648193 DOI 10.1152/ajpheart.00107.2006
McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC (2006)
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
Hypertension, 47 (5), 874-80
PubMed 16585413 DOI 10.1161/01.HYP.0000216794.24161.8c
Chen HH, Schirger JA, Cataliotti A, Burnett JC (2006)
Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
Eur J Heart Fail, 8 (7), 681-6
PubMed 16459135 DOI 10.1016/j.ejheart.2005.12.005
Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC (2005)
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
Proc Natl Acad Sci U S A, 102 (48), 17442-7
PubMed 16293687 DOI 10.1073/pnas.0508782102
Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC (2005)
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
Kidney Int, 67 (5), 1723-30
PubMed 15840018 DOI 10.1111/j.1523-1755.2005.00269.x
James KD, Cataliotti A, Schirger JA, Plonka S, Burnett JC (2005)
Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide
Curr Med Chem, 12 (12), 1439-47
PubMed 15974994 DOI 10.2174/0929867054020909
Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC (2004)
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
Am J Physiol Regul Integr Comp Physiol, 288 (5), R1093-7
PubMed 15627648 DOI 10.1152/ajpregu.00682.2004